Carregant...
Payers Move Slowly on Test Coverage Decisions
Formulary decisions might be considered a snap when compared to decisions about coverage of a genetic test. The presence – or lack – of credible data to demonstrate cost-effectiveness is usually the touchstone.
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioCommunications LLC
2005
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3564335/ https://ncbi.nlm.nih.gov/pubmed/23393473 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|